Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 3/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000802 | 0.85 | NUDT1 (0.37) | NUDT1PRKCITNFRIPK1MAPK1 | |
| SCHEMBL25285039 | 0.85 | NUDT1 (0.37) | NUDT1PRKCITNFRIPK1MAPK1 | |
| SCHEMBL2211568 | 0.80 | PRKCI (0.42) | PRKCIMAPK1AHRAXL | |
| SCHEMBL31275318 | 0.80 | PRKCI (0.42) | PRKCIMAPK1AHRAXL | |
| SCHEMBL10069068 | 0.78 | NUDT1 (0.38) | NUDT1PRKCITNFRIPK1MKNK1 | |
| SCHEMBL2628940 | 0.77 | PRKCI (0.40) | PRKCIMAPK1AHRAXL | |
| SCHEMBL2633340 | 0.77 | PIK3C3 (0.41) | NUDT1PRKCITNFRIPK1AXL | |
| SCHEMBL1763343 | 0.77 | DYRK1A (0.44) | NUDT1PRKCITNFRIPK1MAPK1 | |
| SCHEMBL2086371 | 0.77 | NUDT1 (0.37) | NUDT1PRKCITNFRIPK1MKNK1 | |
| SCHEMBL31381840 | 0.77 | KDM4E (0.39) | PRKCIAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| EP-2975038-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK(NO 4) LTD (GB) | 2017-07-12 | — | — | EP | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| CN-1688311-A | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549313-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-07-06 | — | — | EP | disclosed |
| CN-1612763-A | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | CN | disclosed |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | NUDT1 103/4885PRKCI 1591/4885TNF 400/4885 |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NUDT1 423/4885PRKCI 1446/4885TNF 3023/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NUDT1 423/4885PRKCI 1446/4885TNF 3023/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | NUDT1 22/4885PRKCI 3395/4885TNF 250/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | NUDT1 542/4885PRKCI 1254/4885TNF 3083/4885 |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | NUDT1 103/4885PRKCI 1591/4885TNF 400/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | NUDT1 423/4885PRKCI 1446/4885TNF 3023/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NUDT1 423/4885PRKCI 1446/4885TNF 3023/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | NUDT1 631/4885PRKCI 1970/4885TNF 637/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | NUDT1 423/4885PRKCI 1446/4885TNF 3023/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | NUDT1 74/4885PRKCI 2931/4885TNF 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.